EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Phase Ib, open‐label, fixed‐sequence, drug–drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine

Andrew M Blumenfeld, Ramesh Boinpally, Rosa De Abreu Ferreira, Joel M Trugman, Brett Dabruzzo, Jessica Ailani, Richard B Lipton

Headache: The Journal of Head and Face Pain · 2023

DOI: 10.1111/head.14433 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Headache: The Journal of Head and Face Pain, 2023. Verfasst von Andrew M Blumenfeld und 6 weiteren Autor:innen. Beteiligte Einrichtung: Headache Center of Southern California, Carlsbad, California, USA. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide Receptor Antagonists, Migraine Disorders. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate potential drug–drug interactions of ubrogepant and atogepant.

Background

Ubrogepant and atogepant, calcitonin gene‐related peptide (CGRP) receptor antagonists, are recently approved drugs for acute and preventive treatment of migraine, respectively. For patients with migraine who are prescribed atogepant for the preventive treatment of migraine, health care providers could prescribe ubrogepant for the acute treatment of breakthrough migraine attacks.

Methods

A phase Ib, multi‐center, open‐label, fixed‐sequence study was conducted in participants diagnosed with migraine for at least 1 year. To assess the primary objective of pharmacokinetic interactions in this phase I trial, the highest United States Food and Drug Administration‐approved individual dose strengths of atogepant (60 mg once daily) and ubrogepant (100 mg) were utilized, with ubrogepant being administered on a fixed‐dose schedule every 3 days, regardless of whether a participant was experiencing a migraine attack. Secondary endpoints included safety and tolerability. Clinical safety measurements were monitored throughout the study.

Results

Of the 31 participants enrolled, 26 completed the study. A single dose of ubrogepant had no statistically significant effect on atogepant pharmacokinetics. Co‐administration of ubrogepant with atogepant resulted in a 19% increase (geometric mean ratio 118.80, 90% confidence interval [CI] 108.69–129.84) in the ubrogepant area under the plasma concentration‐time curve and a 26% increase (geometric mean ratio 125.63, 90% CI 105.58–149.48) in the ubrogepant maximum plasma concentration. These statistically significant changes in ubrogepant exposure were not clinically meaningful, and no new safety concerns were identified for the combination.

Conclusion

The combination use of atogepant and ubrogepant was safe and well tolerated in adult participants with a history of migraine enrolled in the study. Pharmacokinetic changes during co‐administration were not clinically meaningful.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcitonin Gene-Related Peptide Receptor AntagonistsMigraine DisordersAdultHumansDrug InteractionsPyridinesPyrrolesPiperidinesSpiro Compounds

Stichwörter der Autor:innen

CGRP receptor antagonistsatogepantdrug-drug interactionmigraineubrogepant

Substanzen

Calcitonin Gene-Related Peptide Receptor AntagonistsubrogepantPyridinesPyrrolesatogepantPiperidinesSpiro Compounds

Autor:innen und Institutionen

  • Headache Center of Southern California, Carlsbad, California, USA.
  • Clinical Pharmacology, AbbVie Inc., Madison, New Jersey, USA.
  • MedStar Georgetown University Hospital, Washington, District of Columbia, USA.
  • The Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, New York, USA.

Förderung

  • AbbVie

Zitieren

APA

Blumenfeld, A. M., Boinpally, R., De Abreu Ferreira, R., Trugman, J. M., Dabruzzo, B., Ailani, J., & Lipton, R. B. (2023). Phase Ib, open‐label, fixed‐sequence, drug–drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14433

Vancouver

Blumenfeld AM, Boinpally R, De Abreu Ferreira R, Trugman JM, Dabruzzo B, Ailani J, et al. Phase Ib, open‐label, fixed‐sequence, drug–drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine. Headache: The Journal of Head and Face Pain. 2023. doi:10.1111/head.14433

BibTeX
@article{Blumenfeld2023,
  author = {Blumenfeld, Andrew M and Boinpally, Ramesh and De Abreu Ferreira, Rosa and Trugman, Joel M and Dabruzzo, Brett and Ailani, Jessica and Lipton, Richard B},
  title = {Phase Ib, open‐label, fixed‐sequence, drug–drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2023},
  doi = {10.1111/head.14433}
}
Kostenlos starten →